It hasn't been easy to stay bullish on BioMimetic Therapeutics (BMTI),
as the stock has stagnated while the company worked to resubmit its PMA
for its Augment bone graft product. What's more, news about
under-reported side-effects and over-promised for Medtronic's (MDT)
Infuse BMP-2 protein has not led doctors nor analysts to have
especially warm and fuzzy feelings about the orthobiologics space. All
of that said, there remains a real medical need for this product, and
the efficacy data on Augment is such that I believe there is a
legitimate bull case to be made on BioMimetic.
Please continue reading here:
Keeping The Faith On BioMimetic Therapeutics
No comments:
Post a Comment